Scarica l'app Stockscreener
5.1485
1.90%
-0.1015
Rezolute Inc Borsa (RZLT) Ultime notizie
Where are the Opportunities in (RZLT) - Stock Traders Daily
Federated Hermes Inc. Has $48.50 Million Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT) - MarketBeat
US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - MSN
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of “Buy” by Brokerages - Defense World
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $10.75 - MarketBeat
Rezolute Inc (RZLT) rating initates by Guggenheim - Knox Daily
Rezolute (NASDAQ:RZLT) Given New $15.00 Price Target at BTIG Research - Defense World
Rezolute shares maintain Buy rating from H.C. Wainwright on FDA update - Investing.com Canada
Rezolute Gains 13%, Insider Trades Reap Benefit - Simply Wall St
Rezolute (NASDAQ:RZLT) Price Target Raised to $15.00 - MarketBeat
Rezolute Inc (RZLT) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study - Yahoo Finance
RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study - Zacks Investment Research
Rezolute (NASDAQ:RZLT) Receives Buy Rating from HC Wainwright - Defense World
FDA authorises US trial of Rezolute’s drug candidate for congenital hyperinsulinism - Yahoo Finance
US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - ETHealthWorld
Rezolute's (RZLT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
RZLT’s latest rating updates from top analysts. - Knox Daily
US FDA lifts partial clinical hold on Rezolute’s blood sugar treatment - WHBL
Peninsula drug maker plots late-stage clinical trial after FDA lifts delay - San Francisco Business Times
Jones Trading maintains Buy rating on Rezolute shares with no price target change - Investing.com Canada
RZLT’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Healthy Upside Potential: Rezolute Inc (RZLT) - SETE News
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment - Benzinga
US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - Reuters
Rezolute rises as FDA lifts clinical hold on hyperinsulinism therapy (NASDAQ:RZLT) - Seeking Alpha
US FDA lifts partial clinical hold on Rezolute’s low blood sugar treatment - PharmaLive
FDA lifts hold on Rezolute's hyperinsulinism therapy study - Investing.com
US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - AOL
Rezolute Shares Rise Premarket After FDA Lifts Partial Study Holds - MarketWatch
Rezolute’s RZ358 Advances with FDA Clearance for Study - TipRanks
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study - StockTitan
Pleasing Signs As A Number Of Insiders Buy Rezolute Stock - Yahoo Finance
Guggenheim Initiates Coverage of Rezolute (RZLT) with Buy Recommendation - Nasdaq
Rezolute (NASDAQ:RZLT) Coverage Initiated by Analysts at Guggenheim - Defense World
Rezolute (NASDAQ:RZLT) Receives New Coverage from Analysts at Guggenheim - MarketBeat
Rezolute to Participate in Upcoming Investor Conferences - StockTitan
BTIG Research gives a Buy recommendation for Rezolute Inc (RZLT) - Knox Daily
Vanguard Group Inc. Grows Stock Position in Rezolute, Inc. (NASDAQ:RZLT) - MarketBeat
Vanguard Group Inc. Buys 145,700 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Contrasting Atreca (NASDAQ:BCEL) and Rezolute (NASDAQ:RZLT) - Defense World
Virtu Financial LLC Acquires Shares of 14,410 Rezolute, Inc. (NASDAQ:RZLT) - Defense World
BTIG Research initates Rezolute Inc (RZLT) stock to a Buy - Knox Daily
Rezolute’s (RZLT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Rezolute (NASDAQ:RZLT) PT Raised to $10.00 - Defense World
HC Wainwright Reaffirms "Buy" Rating for Rezolute (NASDAQ:RZLT) - MarketBeat
Rezolute (NASDAQ:RZLT) Given New $10.00 Price Target at Maxim Group - MarketBeat
FDA clears Rezolute's phase 3 trial for rare disease therapy - Investing.com
FDA clears Rezolute's phase 3 trial for rare disease therapy - Investing.com India
FDA clears Rezolute's phase 3 trial for rare disease therapy By Investing.com - Investing.com UK
Rezolute Receives FDA Nod for Hypoglycemia Drug RZ358 - TipRanks
Rezolute Application for Hypoglycemia Treatment Gets FDA Clearance - MarketWatch
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of - EIN News
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - ForexTV.com
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - StockTitan
Rezolute (NASDAQ:RZLT) Stock Quotes, Forecast and News Summary - Benzinga
Rezolute to Participate in the BTIG Virtual Biotechnology Conference - StockTitan
2seventy bio (NASDAQ:TSVT) and Rezolute (NASDAQ:RZLT) Critical Comparison - Defense World
Comparing Rezolute (NASDAQ:RZLT) and Dynavax Technologies (NASDAQ:DVAX) - Defense World
Acadian Asset Management LLC Invests $229,000 in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Inc [RZLT] Investment Guide: What You Need to Know - Knox Daily
Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of “Buy” from Brokerages - Defense World
1.28%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):